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OBJECTIVES We sought to determine whether a simple index of pressure wave reflection may be derived
from the digital volume pulse (DVP) and used to examine endothelium-dependent vasodi-
lation in patients with type II diabetes mellitus.
BACKGROUND The DVP exhibits a characteristic notch or inflection point that can be expressed as percent
maximal DVP amplitude (IPDVP). Nitrates lower IPDVP, possibly by reducing pressure wave
reflection. Response of IPDVP to endothelium-dependent vasodilators may provide a measure
of endothelial function.
METHODS The DVP was recorded by photoplethysmography. Albuterol (salbutamol) and glyceryl
trinitrate (GTN) were administered locally by brachial artery infusion or systemically. Aortic
pulse wave transit time from the root of the subclavian artery to aortic bifurcation (TAo) was
measured by simultaneous Doppler velocimetry.
RESULTS Brachial artery infusion of drugs producing a greater than threefold increase in forearm blood
flow within the infused limb was without effect on IPDVP, whereas systemic administration
of albuterol and GTN produced dose-dependent reductions in IPDVP. The time between the
first and second peak of the DVP correlated with TAo (r 5 0.75, n 5 20, p , 0.0001). The
effects of albuterol but not GTN on IPDVP were attenuated by N
G-monomethyl-L-arginine.
The IPDVP response to albuterol (400 mg by inhalation) was blunted in patients with type II
diabetes mellitus as compared with control subjects (fall 5.9 6 1.8% vs. 11.8 6 1.8%, n 5 20,
p , 0.02), but that to GTN (500 mg sublingually) was preserved (fall 18.3 6 1.2% vs. 18.6 6
1.9%, p 5 0.88).
CONCLUSIONS The IPDVP is influenced by pressure wave reflection. The effects of albuterol on IPDVP are
mediated in part through the nitric oxide pathway and are impaired in patients with type II
diabetes. (J Am Coll Cardiol 1999;34:2007–14) © 1999 by the American College of
Cardiology
Transmission of infrared light through the finger is propor-
tional to blood volume, and its measurement, “photo-
plethysmography,” gives a digital volume pulse (DVP) (Fig.
1). The DVP exhibits a characteristic “notch” or point of
inflection (IPDVP) in its downslope. It has long been
recognized that nitrovasodilators such as glyceryl trinitrate
(GTN) produce marked changes in the pulse waveform
with a reduction in IPDVP (1–3). Accompanying changes in
heart rate and blood pressure are minor in comparison to
those in the DVP, and IPDVP has been used as a sensitive
index of nitrate bioavailability (4). More recently, acetylcho-
line, which acts by stimulating release of nitric oxide (NO)
from the endothelium, has been shown to lower the height
of a similar inflection point in the photoplethysmographic
waveform recorded from the rabbit ear (5). This response to
acetylcholine in rabbits is antagonized by inhibition of NO
synthase and is reduced in cholesterol-fed rabbits, suggest-
ing that it may be used as a measure of endothelial function
(5). In Japan the second derivative of the DVP has been
widely used by Takazawa et al. (6) to assess effects of
vasoactive drugs and characterize vascular aging.
Despite the well-recognized effects of vasodilator drugs
and aging on the DVP, the physical properties determining
its characteristics remain poorly understood. The fall in
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IPDVP after GTN has been variously attributed to a “Wind-
kessel” effect resulting from increased compliance of large
arteries and to decreased venous return to the heart (5,7).
The pressure pulse has been studied more extensively than
the volume pulse (8), and changes in the pressure pulse
caused by GTN are thought to result mainly from decreased
pressure wave reflection (9–11). Although infrared light
transmission through the finger can, in combination with a
servocontrolled finger pressure cuff, be used to derive a
pressure pulse (12), the DVP obtained by simple photo-
plethysmography and pressure pulse waveforms differ and
their relation is complex (13). Changes in the DVP pro-
duced by GTN do, however, parallel those in the pressure
pulse (13). Decreased pressure wave reflection might there-
fore account for effects of GTN on the DVP. The purpose
of the present study was to investigate the factors that
influence the DVP in humans and to explore the use of the
DVP in detecting abnormalities in vascular reactivity in
patients with type II diabetes mellitus, a group known to
exhibit marked endothelial dysfunction (14–16). We mea-
sured the effects of local and systemic administration of
vasodilators on the DVP, and compared the time interval
between components of the DVP with aortic pulse wave
transit time (TAo). Aortic pulse wave velocity (PWVAo) was
calculated from TAo and aortic length. The PWVAo is an
accepted measure of aortic compliance (17,18). We com-
pared the effects of vasodilators on DVP, PWVAo and
peripheral vascular resistance, and we examined the effects
of altering wave reflection from the lower body by supra-
systolic leg cuff inflation.
Our results suggested that the DVP comprises a direct
component arising from pressure waves propagating from
the heart to the finger and a delayed component arising
from pressure waves reflected backward from peripheral
arteries mainly in the lower body, which then propagate to
the finger. In further studies IPDVP was used to assess the
effects of the beta2-adrenergic agonist albuterol (salbuta-
mol). We have previously shown that the vasodilator effects
of albuterol on forearm resistance arteries are mediated, in
part, through the L-arginine–NO pathway (19). To deter-
mine whether the effects of albuterol on the DVP are
similarly dependent on this pathway, we performed studies
in the presence and absence of an NO synthase inhibitor,
NG-monomethyl-L-arginine (L-NMMA). Finally we com-
pared the effects of albuterol and GTN on the DVP in
patients with uncomplicated type II diabetes and healthy
control subjects.
METHODS
Subjects. Healthy volunteers, recruited from the local com-
munity by advertisement, were screened by physical exam-
ination and routine biochemistry. All were normotensive
(office blood pressure ,140/90 mm Hg) and none had total
serum cholesterol values .230 mg/dl. Patients with type II
diabetes were recruited from the Diabetic Clinic at St.
Thomas’ Hospital; they were managed by diet or by diet
plus oral hypoglycemic therapy. No patients had complica-
tions other than background diabetic retinopathy, and none
were receiving vasoactive drug therapy. The characteristics
of the subjects participating in the sub-study of the com-
parison of the DVP between patients with type II diabetes
and control subjects are shown in Table 1. Control subjects
in this sub-study were recruited concurrently with patients
with diabetes and were similar in terms of age and gender
distribution. Subjects in all other studies were male volun-
teers. The study was approved by St. Thomas’ Hospital
Research Ethics Committee, and all subjects gave written,
informed consent.
Photoplethysmography. A photoplethysmograph (Micro
Medical, Gillingham, Kent, United Kingdom) transmitting
infrared light at 940 nm was placed on the index finger of
Abbreviations and Acronyms
DVP 5 digital volume pulse
GTN 5 glyceryl trinitrate
IPDVP 5 inflection point in digital volume pulse
expressed as percent DVP amplitude
iv 5 intravenous
LAo 5 distance from the root of the subclavian
artery to the bifurcation of the aorta
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
PWVAo 5 aortic pulse wave velocity
sl 5 sublingual
TAo 5 aortic pulse wave transit time (root of
subclavian artery to aortic bifurcation)
DTDVP 5 time between first and second peak of
digital volume pulse
Figure 1. The digital volume pulse (DVP) and first derivative
(dV/dt, lower trace) recorded before and after systemic adminis-
tration of GTN (500 mg sublingually). The notch or point of
inflection at height, b, is identified by the local maximum in the
first derivative. The height of the inflection point (IPDVP) is
expressed as percent DVP amplitude, a. The IPDVP falls after
GTN. The time between the first and second peak of the DVP
(DTDVP) was measured in some experiments.
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the right hand (except in experiments involving brachial
artery infusion when bilateral measurements were made).
Frequency response of the photoplethysmograph was flat to
10 Hz. Digital output from the photoplethysmograph was
recorded through an analogue-to-digital converter (12 bit,
sampling frequency 100 Hz). The first derivative with
respect to time of the DVP signal was used to identify the
notch or inflection point as the point, after the first peak of
the waveform, at which the first derivative was at a local
maximum. The IPDVP was taken as the height of this point
(b) expressed as percent amplitude of the waveform (a):
IPDVP 5 b/a 3 100% (Fig. 1). The IPDVP was calculated
from the mean of three or more consecutive cycles of the
DVP. In some experiments the time between the first and
second peak of the DVP (DTDVP) (Fig. 1) was measured.
All measurements were made with the subject supine in a
temperature-controlled laboratory at 26 6 1°C. All subjects
were allowed to acclimatize to this temperature for at least
30 min before recordings commenced.
Photoplethysmographic measurements during brachial
artery infusion of vasodilators. Bilateral DVP and fore-
arm blood flow measurements were made simultaneously
during brachial artery administration of albuterol and GTN.
The brachial artery was cannulated using a 27-gauge steel
needle (Coopers Needleworks, Birmingham, United King-
dom) using ,0.25 ml of 1% lidocaine as local anesthetic.
Drugs diluted in 0.9% saline and saline alone were infused
at 1 ml/min. Forearm blood flow was measured in both
arms by venous occlusion strain gauge plethysmography
(20) electrically calibrated (21). Wrist cuffs were not used so
as to include the contribution (;50%) from the hand to
total forearm blood flow (22). After baseline measurements
during infusion of saline alone, the DVP and blood flow
were measured during infusions of four cumulative doses
(0.1, 0.3, 1.0 and 3.0 mg/min) of albuterol (Allen and
Hanburys, United Kingdom) or four cumulative doses of
GTN (0.1, 0.3, 1.0 and 3.0 mg/min) (David Bull Labora-
tories, Australia). Each dose was infused for 5 min with
blood flow (mean of five venous occlusions) measured
during the last 2 min of each infusion period. The DVP
recordings were obtained immediately after forearm blood
flow measurements.
Photoplethysmographic measurements during systemic
administration of vasodilators and leg cuff inflation. The
DVP recordings were obtained during administration of
GTN, 500 mg sublingual (sl) for 5 min and 10 to
100 mg/min intravenous (iv) and albuterol 100 to 400 mg by
inhalation through a spacer or 2 to 20 mg/min iv. During sl
administration of GTN, changes in IPDVP were maximal
between 3 and 5 min. The mean of measurements over this
period was used to quantify the response to sl GTN. The
response to inhaled albuterol was taken as the mean of
measurements at 10 and 15 min after inhalation. This
avoided artifactual responses relating to the inhalational
maneuver (assessed using a placebo inhaler), which resolved
within 5 min. Responses to iv administration of GTN and
albuterol were measured after the attainment of steady state
or when responses were maximal. In some experiments
simultaneous measurements of PWVAo, derived from aortic
transit times as described subsequently, were made before,
during and after administration of GTN and albuterol.
Changes in IPDVP were also measured before and after
bilateral suprasystolic leg cuff inflation.
Measurement of TAo: Comparison with DTDVP. The TAo
was measured from the “foot to foot” delay time between
Doppler velocity sonograms obtained using 4-MHz contin-
uous wave transducers (Sonicaid, BV 380, Oxford, United
Kingdom). One transducer was placed in the left anterior
triangle of the neck to insonate the root of the left
subclavian artery and the other at the midpoint between the
anterior superior iliac spines to insonate the abdominal aorta
just above the aortic bifurcation. Real-time spectral analysis
was used to obtain the maximal frequency envelopes of the
Doppler signals and the “foot to foot” transit time between
these obtained as previously described (23). The distance
Table 1. Characteristics of Patients With Type II Diabetes Mellitus and Control Subjects
Control Subjects
(n 5 20)
Diabetics
(n 5 20)
Gender (M/F) 15/5 13/7
Smokers/nonsmokers 4/16 5/15
Age (yrs) 44 6 6.9 48 6 10
Systolic BP (mm Hg) 123 6 17 131 6 21
Diastolic BP (mm Hg) 71 6 13 78 6 12
BMI (kg/m2) 24 6 2.5 28 6 4.7*
Glucose (mmol/liter) 4.8 6 0.6 10.3 6 5.3*
HbA1c (%) 4.9 6 0.6 7.7 6 2.0*
Total cholesterol (mg/dl) 189 6 31 201 6 46
Triglycerides (mg/dl) 115 6 71 230 6 186
HDL cholesterol (mg/dl) 54 6 12 46 6 12
*p , 0.05 compared with control subjects. Data are presented as mean value 6 SD.
BP 5 blood pressure; BMI 5 body mass index; HbA1c 5 glycogylated hemoglobin; HDL 5 high density lipoprotein.
2009JACC Vol. 34, No. 7, 1999 Chowienczyk et al.
December 1999:2007–14 Pulse Wave Reflection in Type II Diabetes Mellitus
from the root of the subclavian artery to the bifurcation of
the aorta (LAo) was measured from surface markings (24).
The PWVAo was calculated from LAo/TAo (23). This
method is similar to that described by Avolio et al. (17,18).
The TAo was compared with the DTDVP. In two subjects
the second peak of the DVP was not clearly defined, and in
these subjects the first derivative was used to identify the
time of the second peak.
Effects of L-NMMA on the DVP response to albuterol
and GTN. The IPDVP response to albuterol (400 mg by
inhalation) was assessed 15 min after administration of
L-NMMA (3 mg/kg IV over 5 min), and on another
occasion, separated by at least one week, after saline placebo
in a two-phase randomized crossover study. We and other
investigators have previously established that the response to
this dose of L-NMMA is maximal at ;15 min (25,26). The
response to GTN (500 mg sl) was measured after the same
dose of L-NMMA and saline placebo in the same study
design. In addition to IPDVP, mean arterial blood pressure
(Dinamap model 1846 SX, Critikon, Florida) and cardiac
output (bioimpedance cardiac output monitor: BoMed
NCCOM3, BoMed Medical Manufacturing Ltd, Califor-
nia) were measured noninvasively using previously validated
methods (27,28). Total systemic vascular resistance was
estimated by dividing mean arterial pressure by cardiac
output. All measurements were made with subjects supine.
DVP responses in patients with type II diabetes and
control subjects. After 30 min rest supine basal measure-
ments of IPDVP, pulse rate and blood pressure were ob-
tained at 5 min intervals for 15 min. Glyceryl trinitrate
(500 mg sl) was then administered and measurements
obtained at 1-min intervals for 5 min and at 5-min intervals
for 30 min, by which time all hemodynamic values had
returned to baseline. Albuterol (400 mg by inhalation
through spacer) was given and further measurements were
made at 5-min intervals for 20 min. Responses to GTN and
albuterol were assessed as described earlier.
Statistics. Subject characteristics are presented as the mean
value 6 SD. Results are presented as the mean value 6 SE.
Analysis of variance for repeated measures was used to test
for differences in IPDVP and other hemodynamic measure-
ments. The Mann-Whitney U test was used to test for
differences in IPDVP response between patients with dia-
betes and control subjects. Correlation between TAo and
DTDVP was sought using least squares regression analysis.
Differences were considered significant at p , 0.05 (two-
tailed).
RESULTS
Brachial artery infusion of vasodilators. Brachial artery
infusion of albuterol (0.1 to 3 mg/min) increased total blood
flow in the infused arm from 4.9 6 0.7 ml/min per 100 ml
forearm to 24.5 6 3.3 ml/min per 100 ml (p , 0.001), but
had no significant effect on forearm blood flow in the
noninfused arm. Brachial artery infusion of albuterol in-
creased the amplitude of the DVP waveform but produced
no significant change in IPDVP in the infused or noninfused
arm. The ratio of forearm blood flow in the infused to
noninfused arm increased more than threefold, while the
ratio of the IPDVP in the infused to noninfused arm
remained constant to within 10% (p , 0.001 for compari-
son of blood flow ratio and IPDVP ratio) (Fig. 2). Brachial
artery infusion of GTN (0.1 to 3 mg/min) increased forearm
blood flow in the infused arm from 9.8 6 2.0 to 22.4 6
2.4 ml/min per 100 ml (p , 0.01) but had no significant
effect on forearm blood flow in the noninfused arm. Brachial
artery infusion of GTN was associated with a small but
significant fall in IPDVP of the infused arm (60 6 5.5% to
53 6 5.8%, p , 0.05), but IPDVP of the noninfused arm fell
to a similar degree (63 6 5.1% to 49 6 6.3%) so that the
ratio of the IPDVP in the infused to noninfused arm
remained constant (p , 0.001 for comparison of blood flow
ratio and IPDVP ratio) (Fig. 2).
Systemic administration of vasodilators and leg cuff
inflation. Albuterol (100 to 400 mg by inhalation and 25 to
100 mg iv bolus and 2 to 20 mg/min iv) and GTN (500 mg
sl and 10 to 100 mg/min iv) reduced IPDVP (Fig. 3).
Changes from baseline in IPDVP and in systemic hemody-
namic values after albuterol (400 mg by inhalation) and
GTN (500 mg sl) in 10 healthy volunteers are shown in
Figure 4. Reductions in IPDVP of 16.8 6 3.2% (26.2 6
5.7% change from baseline) and 24.0 6 1.9% (40.4 6 4.2%
change from baseline) after albuterol and GTN, respec-
tively, were accompanied by relatively minor changes in
heart rate (increase of 12.9 6 2.9 and 6.4 6 2.3 beats/min
for albuterol and GTN, respectively, each p , 0.05) and
blood pressure (changes in systolic blood pressure of 5.1 6
2.7 and 24.0 6 3.0 mm Hg, each p 5 NS, and decreases
in diastolic blood pressure of 3.2 6 1.8 mm Hg [p 5 NS]
and 4.9 6 1.6 mm Hg [p , 0.05] for albuterol and GTN,
respectively). Systemic vascular resistance fell by 26 6 3.6%
and 16 6 3.4% and cardiac output increased by 30 6 5.5%
and 8.2 6 3.1% (each p , 0.05) after albuterol and GTN,
respectively. In experiments where PWVAo and IPDVP were
Figure 2. Ratios of forearm blood flow (FBF, open squares) and
inflection point of the digital volume pulse (IPDVP, circles) in the
infused-noninfused arms during brachial artery infusion of albu-
terol (ALB, n 5 5) and glyceryl trinitrate (GTN, n 5 5).
2010 Chowienczyk et al. JACC Vol. 34, No. 7, 1999
Pulse Wave Reflection in Type II Diabetes Mellitus December 1999:2007–14
measured simultaneously, changes in IPDVP after adminis-
tration of albuterol or GTN were not accompanied by
significant changes in PWVAo (Fig. 5). Bilateral suprasys-
tolic leg cuff inflation increased IPDVP by 13.3 6 2.5% (n 5
9, p , 0.01).
Comparison of DTDVP with TAo. The DTDVP was corre-
lated with TAo—the delay between the foot of the velocity
sonogram at the subclavian artery and that at the aortic
bifurcation (r 5 0.75, n 5 20, p , 0.0001) (Fig. 6). The
slope of the regression line was 3.9 6 0.81.
Effect of L-NMMA on DVP response to albuterol and
GTN. Changes in IPDVP in response to albuterol were less
when albuterol was administered after L-NMMA as com-
pared with saline placebo (5.4 6 7.5% change from baseline
for albuterol after L-NMMA vs. 26 6 5.7% change from
baseline for albuterol after saline, n 5 10, p , 0.01) (Fig. 4).
In contrast, changes in IPDVP after GTN were similar after
L-NMMA and saline placebo (37.2 6 6.4% change from
baseline for GTN after L-NMMA vs. 40.4 6 4.2% change
from baseline for GTN after saline, n 5 10, p 5 0.68)
(Fig. 4). The increase in cardiac output after both GTN
and albuterol was significantly less after L-NMMA than
after saline placebo (each p , 0.05). Changes in other
hemodynamic values after albuterol and GTN did not
differ significantly according to whether L-NMMA or
saline had been administered, although there was a
tendency for the fall in systemic vascular resistance after
albuterol to be less after L-NMMA than after saline
placebo (p 5 0.09).
Figure 3. Typical DVP traces showing responses to sublingual (s.l.) and intravenous (i.v.) and to inhaled and i.v. albuterol (ALB).
Figure 4. Changes from baseline in hemodynamic measurements
after GTN (n 5 10) and albuterol (ALB, n 5 10) after saline
placebo or L-NMMA administered 15 min before GTN/ALB.
CO 5 cardiac output; DBP 5 diastolic blood pressure; HR 5
heart rate; IPDVP 5 height of inflection point of DVP measured as
percent amplitude; SBP 5 systolic blood pressure; SVR 5 sys-
temic vascular resistance. Percent change from baseline of the
IPDVP refers to change in percent units (e.g., fall from 80% to 60%
5 [80–60]/80 5 25%). *p , 0.05 for L-NMMA vs. saline. **p ,
0.01 for L-NMMA vs. saline. Open box 5 saline; dotted box 5
L-NMMA.
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DVP responses to albuterol and GTN in patients with
type II diabetes. The effects of albuterol and GTN on
heart rate and blood pressure were similar in control subjects
and patients with type II diabetes (Table 2). At baseline
IPDVP was similar in patients with type II diabetes and
control subjects. The fall in IPDVP in response to GTN was
similar in diabetic patients and control subjects (18.3 6
1.2% vs. 18.6 6 1.9%, n 5 20, p 5 0.88). The response to
albuterol in patients with diabetes was significantly less than
that in control subjects (5.9 6 1.8% vs. 11.8 6 1.8%, n 5
20, p , 0.02 by analysis of variance and Mann-Whitney U
test) (Fig. 7). Overall, in all subjects and for both drugs,
there was no correlation between the change in IPDVP and
the change in heart rate (r 5 0.26, p 5 0.24). At the doses
used, GTN produced a greater fall in IPDVP than did
albuterol (p , 0.0001), despite a less marked increase in
heart rate.
DISCUSSION
Photoplethysmography. Photoplethysmography provides
a simple means for deriving the DVP. Although widely used
as a means for displaying the pulse (for example, in pulse
oximetry), its use to study the detail of the shape of the
waveform itself has received surprisingly little attention.
This may be because the peripheral site of recording and the
difference between the DVP and arterial pressure waveform
give the misleading impression that the DVP is influenced
mainly by local factors. However, Takazawa et al. (6) have
shown that the second derivative of the DVP may be used to
Figure 5. Height of the inflection point of the digital volume pulse
relative to the amplitude (IPDVP) and aortic pulse wave velocity
(PWVAo) in healthy men (n 5 5) at baseline, 5 min after GTN
(500 mg sublingually) and after 20 min of recovery.
Figure 6. Correlation between the time from the first to second
peak of the digital volume pulse (DTDVP) and pressure wave transit
time from the root of the subclavian artery to the aortic bifurcation
(TAo) in 20 healthy men (r 5 0.75, p , 0.0001).
Figure 7. Decrease from baseline in the height of the inflection
point of the digital volume pulse (IPDVP) after GTN (500 mg
sublingually) and albuterol (ALB, 400 mg by inhalation through
spacer) in patients with type II diabetes (n 5 20) and control
subjects (n 5 20).
Table 2. Changes in Heart Rate and Blood Pressure After
Albuterol and Glyceryl Trinitrate in Patients With Type II
Diabetes Mellitus and Control Subjects
Control Subjects
(n 5 20)
Diabetics
(n 5 20)
Heart rate (beats/min)
ALB 9.8 6 1.6* 7.1 6 1.2*
GTN 6.5 6 1.2* 5.6 6 1.2*
Systolic BP (mm Hg)
ALB 0.3 6 3.0 1.6 6 3.1
GTN 22.7 6 1.9 25.4 6 2.1
Diastolic BP (mm Hg)
ALB 22.0 6 2.3 26.4 6 2.6
GTN 26.1 6 1.4* 26.7 6 1.4*
*p , 0.05 compared with zero. Data are presented as mean value 6 SD.
ALB 5 albuterol; BP 5 blood pressure; GTN 5 glyceryl trinitrate.
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infer changes in the systemic circulation relating to the effects
of drugs and aging. In the present study, we have focused on
IPDVP—the relative height of the inflection point separating
the systolic and diastolic components of the DVP.
Lack of effect of local vasodilation on IPDVP. We found
that direct infusion of vasodilators into the brachial artery
sufficient to increase total forearm blood flow more than
threefold had little or no effect on IPDVP. The highest dose
of GTN was associated with a small but significant effect on
the IPDVP, but this was similar in the infused and nonin-
fused arms, suggesting that it was due to a systemic rather
than local effect. In contrast, systemic administration of
GTN produced a profound change in IPDVP while having
no significant effect on forearm blood flow. These observa-
tions effectively exclude local circulatory changes in the arm
or hand (which contributes ;50% to forearm blood flow
[22]) as responsible for effects of systemic administration of
albuterol or GTN on IPDVP in normal subjects at an
ambient temperature of 26°C.
Influence of wave reflection. Of the various explanations
that have been suggested to account for the IPDVP that which
best fits our observations is that the DVP is determined by
direct and reflected pressure waves. Reflected waves arising
mainly from the lower body are delayed relative to the direct
wave, and therefore produce an inflection point or second peak
in the DVP. O’Rourke et al. (8,9) have previously suggested
that systemic administration of GTN reduces pressure wave
reflection, and this is consistent with the reduction of IPDVP
seen after systemic but not local administration of GTN in the
present study. Suprasystolic pressure cuff inflation around the
thighs would be expected to increase pressure wave reflection
from the legs, and indeed this was accompanied by an increase
in IPDVP, supporting the concept of the IPDVP being influ-
enced by wave reflection. Further evidence of wave reflection
determining the characteristics of the DVP arises from the
correlation between DTDVP and TAo: if the second peak of the
DVP is caused by pressure waves reflected from peripheral
arteries, then the DTDVP of the DVP waveform would be
expected to be related to the time taken for pressure waves to
pass from the heart to the “site of reflection” and back to the
heart (the transit times for pressure waves to pass from the
heart to the subclavian artery and from the subclavian artery
along the arm to the finger being common for both the direct
and reflected waves). We observed a strong correlation be-
tween DTDVP and the propagation time of pressure waves
along the aorta from the TAo. This correlation again supports
the concept of wave reflection as a major determinant of
IPDVP. Reflections from many sites within the vascular tree are
likely to contribute to the reflected wave seen at the periphery,
resulting in temporal spread of the reflected wave. The time
between the peak of the direct wave and the peak of the
reflected wave cannot, therefore, be used to define precisely the
time taken for pressure waves to pass from sites of reflection to
the upper limb, because there are multiple such sites and
because such timing information would need to be inferred
from the foot to foot delay between direct and reflected waves.
Our observation that DTDVP is approximately four times the
TAo is nevertheless compatible with the suggestion by Yagi-
numa et al. (10), Latson et al. (29) and others (8) that wave
reflection occurs predominantly from small arteries in the trunk
and lower limbs. Because large changes in DVP pulse are
observed in response to GTN in the absence of large changes
in systemic vascular resistance, such arteries must be proximal
to resistance vessels.
Influence on IPDVP of systolic ejection time, heart rate
and pulse wave velocity. Systolic ejection time and heart
rate are likely to influence IPDVP (8). However, in the
present study we found no correlation between the change
in IPDVP and the change in heart rate. Furthermore,
compared with albuterol, GTN produced less increase in
heart rate and cardiac output but a greater fall in IPDVP.
This suggests that the effects of these drugs on IPDVP occur
independently of any effect on heart rate. A change in IPDVP
could occur as a result of vasodilation of the arteries, which
contributes most to wave reflection, thus reducing the
reflected waves as well as IPDVP. Alternatively, decreased
aortic pulse wave velocity, resulting from increased aortic
and large artery compliance (17,18), could delay arrival of
the reflected wave relative to the direct wave, increasing
DTDVP and hence reducing IPDVP. To distinguish between
these possibilities we made simultaneous measurements of
PWVAo and IPDVP during administration of vasodilators.
We found that changes in IPDVP were not accompanied by
changes in PWVAo. This is consistent with the observations
of Yaginuma et al. (10), who found GTN to have no effect
on the timing of vascular reflections. This suggests that
during vasodilator therapy, a reduction in IPDVP is due
mainly to dilation of small arteries reducing wave reflection
from the lower body.
Effect of albuterol on IPDVP as a test of endothelial
function. Vasodilator effects of GTN are mediated
through its metabolism in vascular smooth muscle to NO or
a nitrosothiol (30). Vasodilators that stimulate NO release
from the endothelium through the L-arginine–NO pathway
might therefore be expected to have a similar effect on
IPDVP to GTN. In the present study we found that
albuterol produced a marked change in IPDVP. We and
other investigators have previously shown that beta-
adrenergic agonists—albuterol, in particular—produce va-
sodilation in resistance arteries, which is dependent on the
L-arginine–NO pathway (19,31). To determine whether
the effects of albuterol on the IPDVP are mediated through
the L-arginine–NO pathway, we examined responses to
albuterol in the presence and absence of L-NMMA. We
also examined the effects of L-NMMA on GTN as a
control study. L-NMMA blunted the effect of albuterol on
IPDVP but did not influence the effect of GTN. This
suggests that the effect of albuterol on IPDVP is mediated at
least in part through the L-arginine–NO pathway.
The finding that the IPDVP response to albuterol depends
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on the endothelial L-arginine–NO pathway raises the pos-
sibility that this response may be used to examine the
integrity of this pathway in conditions associated with
endothelial dysfunction. To investigate this, we examined
the response to albuterol (and GTN as an endothelium-
independent control) in patients with type II diabetes. We
chose this group because there is evidence of marked
impairment of endothelium-dependent vasodilation in such
patients (14–16). We found that responses to albuterol in
type II diabetic patients are indeed blunted relative to
nondiabetic control subjects, whereas responses to GTN are
preserved, consistent with a defect in the endothelial L-
arginine–NO pathway in type II diabetes. These findings
therefore suggest that the IPDVP response to albuterol may
be used as a simple test of endothelial function. Its appli-
cation for this will require further validation, however.
Conclusions. Our results suggest that IPDVP is influenced
by wave reflection from the lower body. Glyceryl trinitrate
and albuterol lower IPDVP through vasodilation of arteries
in the lower body. The effects of albuterol are mediated in
part through the L-arginine–NO pathway and are impaired
in patients with type II diabetes. Photoplethysmographic
assessment of the DVP may provide a useful method for
examining vascular reactivity.
Reprint requests and correspondence: Dr. P. J. Chowienczyk,
Department of Clinical Pharmacology, St. Thomas’ Hospital,
Lambeth Palace Road, London SE1 7EH, United Kingdom.
E-mail: p.chowienczyk@umds.ac.uk
REFERENCES
1. Murrell W. Nitroglycerin as a remedy for angina pectoris. Lancet
1879;80:113–5.
2. Dillon JB, Hertzman AB. The form of the volume pulse in the finger
pad in health, arteriosclerosis and hypertension. Am Heart J 1941;21:
172–90.
3. Morikawa Y. Characteristic pulse wave caused by organic nitrates.
Nature 1967;213:841–2.
4. Bass A, Walden R, Hirshberg A, Schneiderman J. Pharmacokinetic
activity of nitrates evaluated by digital pulse volume recording. J Car-
diovasc Surg 1989;30:395–7.
5. Klemsdal TO, Andersson TLG, Matz J, et al. Vitamin E restores
endothelium dependent vasodilatation in cholesterol fed rabbits: in
vivo measurements by photoplethysmography. Cardiovasc Res 1994;
28:1397–402.
6. Takazawa K, Tanaka N, Fujita M, et al. Assessment of vasoactive
agents and vascular ageing by the second derivative of photoplethys-
mograph waveform. Hypertension 1998;32:365–70.
7. Stengele E, Winkler F, Trenk D, et al. Digital pulse plethysmography
as a non-invasive method for predicting drug-induced changes in left
ventricular preload. Eur J Clin Pharmacol 1996;50:279–82.
8. Nichols WW, O’Rourke MF. McDonald’s Blood Flow in Arteries:
Theoretical, Experimental and Clinical Principles. London: Arnold,
1998.
9. O’Rourke MF, Kelly R, Avolio A. The Arterial Pulse. Malvern (PA):
Lea & Febiger, 1992.
10. Yaginuma T, Avolio A, O’Rourke M, et al. Effect of glyceryl trinitrate
on peripheral arteries alters left ventricular hydraulic load in man.
Cardiovasc Res 1986;20:153–60.
11. Kelly RP, Gibbs HH, O’Rourke MF, et al. Nitroglycerin has more
favourable effects on left ventricular afterload than apparent from
measurement of pressure in a peripheral artery. Eur Heart J 1990;11:
138–44.
12. Imholz BP, Wieling W, van Montfrans GA, Wesseling KH. Fifteen
years experience with finger arterial pressure monitoring: assessment of
the technology. Cardiovasc Res 1998;38:605–16.
13. Millasseau SC, Bland JE, Kelly RP, et al. Comparison of effects of
GTN on the digital volume and radial pressure pulse waveforms
(abstr). Br J Clin Pharmacol 1999;16:2218.
14. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired
endothelium-dependent and independent vasodilation in patients with
type 2 (non–insulin-dependent) diabetes mellitus. Diabetologia 1992;
35:771–6.
15. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide–
mediated vasodilation in patients with non–insulin-dependent diabetes
mellitus. J Am Coll Cardiol 1996;27:567–74.
16. Watts GF, O’Brien SF, Silvester W, Millar JA. Impaired
endothelium-dependent and independent dilation of forearm resis-
tance arteries in men with diet treated non–insulin-dependent diabe-
tes: role of dyslipidaemia. Clin Sci 1996;91:567–73.
17. Avolio AP, Chen SG, Wang RP, et al. Effects of aging on changing
arterial compliance and left ventricular load in a northern Chinese
urban community. Circulation 1983;68:50–8.
18. Avolio AP, Deng FQ, Li WQ, et al. Effects of aging on arterial
distensibility in populations with high and low prevalence of hyper-
tension: comparison between urban and rural communities in China.
Circulation 1985;71:202–10.
19. Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhibition of the
L-arginine/nitric oxide pathway on vasodilation caused by beta-
adrenergic agonists in human forearm. Circulation 1997;95:2293–7.
20. Whitney RJ. The measurement of volume changes in human limbs.
J Physiol (Lond) 1953;121:1–27.
21. Hokanson DE, Sumner DS, Strandness DE Jr. An electrically
calibrated plethysmograph for direct measurement of limb blood flow.
IEEE Trans Biomed Eng 1975;22:25–9.
22. Kerslake DM. The effect of the application of an arterial occlusion cuff
to the wrist on the blood flow in the human forearm. J Physiol (Lond)
1949;108:451–7.
23. Lehmann ED, Hopkins KD, Rawesh A, et al. Relation between
number of cardiovascular risk factors/events and noninvasive Doppler
ultrasound assessments of aortic compliance. Hypertension 1998;32:
565–9.
24. Lehmann ED, Gosling RG, Fatemi-Langroudi B, Taylor MG.
Non-invasive Doppler ultrasound technique for the in vivo assessment
of aortic compliance. J Biomed Eng 1992;14:250–6.
25. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric
oxide synthesis increases blood pressure in healthy humans. J Hyper-
tens 1993;11:1375–80.
26. Brett SE, Cockcroft JR, Mant TGK, et al. Haemodynamic effects of
inhibition of nitric oxide synthase and of L-arginine at rest and during
exercise. J Hypertens 1998;16:429–35.
27. Northridge DB, Findlay IN, Wilson J, et al. Non-invasive determi-
nation of cardiac output by Doppler echocardiography and electrical
bioimpedance. Br Heart J 1990;63:93–7.
28. Thomas SHL. Impedance cardiography using the Sramek-Berstein
method: accuracy and reproducibility at rest and during exercise. Br J
Clin Pharmacol 1992;34:467–76.
29. Latson TW, Hunter WC, Katoh N, Sagawa K. Effect of nitroglycerin
on aortic impedance, diameter and pulse wave velocity. Circ Res
1988;62:884–90.
30. Feelisch M. Biotransformation to nitric oxide of organic nitrates in
comparison to other nitrovasodilators. Eur Heart J 1993;14:123–32.
31. Cardillo C, Kilcoyne CM, Quyyumi AA, et al. Decreased vasodilator
response to isoproterenol during nitric oxide inhibition in humans.
Hypertension 1997;30:918–21.
2014 Chowienczyk et al. JACC Vol. 34, No. 7, 1999
Pulse Wave Reflection in Type II Diabetes Mellitus December 1999:2007–14
